首页> 美国卫生研究院文献>International Journal of Nanomedicine >Enhanced oral bioavailability of valsartan using a polymer-based supersaturable self-microemulsifying drug delivery system
【2h】

Enhanced oral bioavailability of valsartan using a polymer-based supersaturable self-microemulsifying drug delivery system

机译:使用基于聚合物的超饱和自微乳化药物递送系统增强缬沙坦的口服生物利用度

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A novel, supersaturable self-microemulsifying drug delivery system (S-SMEDDS) was successfully formulated to enhance the dissolution and oral absorption of valsartan (VST), a poorly water-soluble drug, while reducing the total quantity for administration. Poloxamer 407 is a selectable, supersaturating agent for VST-containing SMEDDS composed of 10% Capmul® MCM, 45% Tween® 20, and 45% Transcutol® P. The amounts of SMEDDS and Poloxamer 407 were chosen as formulation variables for a 3-level factorial design. Further optimization was established by weighting different levels of importance on response variables for dissolution and total quantity, resulting in an optimal S-SMEDDS in large quantity (S-SMEDDS_LQ; 352 mg in total) and S-SMEDDS in reduced quantity (S-SMEDDS_RQ; 144.6 mg in total). Good agreement was observed between predicted and experimental values for response variables. Consequently, compared with VST powder or suspension and SMEDDS, both S-SMEDDS_LQ and S-SMEDDS_RQ showed excellent in vitro dissolution and in vivo oral bioavailability in rats. The magnitude of dissolution and absorption-enhancing capacities using quantity-based comparisons was in the order S-SMEDDS_RQ > S-SMEDDS_LQ > SMEDDS > VST powder or suspension. Thus, we concluded that, in terms of developing an effective SMEDDS preparation with minimal total quantity, S-SMEDDS_RQ is a promising candidate.
机译:成功配制了一种新型的,过饱和的自微乳化药物输送系统(S-SMEDDS),以增强水溶性差的药物缬沙坦(VST)的溶解和口服吸收,同时减少给药总量。 Poloxamer 407是含VST的SMEDDS的一种可选的过饱和剂,它由10%Capmul MCM,45%Tween ® 20和45%Transcutol ®<选择SMEDDS和Poloxamer 407的量作为三级因子设计的配方变量。通过对溶出度和总量的响应变量加权不同的重要性级别来建立进一步的优化,从而得到大量的最佳S-SMEDDS(S-SMEDDS_LQ;总计352 mg)和减少量的S-SMEDDS(S-SMEDDS_RQ) ;总计144.6 mg)。在响应变量的预测值和实验值之间观察到良好的一致性。因此,与VST粉末或混悬液以及SMEDDS相比,S-SMEDDS_LQ和S-SMEDDS_RQ在大鼠中均表现出优异的体外溶出度和体内口服生物利用度。使用基于数量的比较,溶出度和吸收增强能力的大小顺序为S-SMEDDS_RQ> S-SMEDDS_LQ> SMEDDS> VST粉末或悬浮液。因此,我们得出结论,就开发具有最小总量的有效SMEDDS制剂而言,S-SMEDDS_RQ是有前途的候选人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号